Grail Bio plans to raise more than $1 billion from undisclosed strategic industry partners and other investors. Grail has hired The Goldman Sachs Group, Inc. (NYSE:GS) to handle the massive deal, which is expected to close before March 31, 2016. Illumina, Inc. (NasdaqGS:ILMN) , which holds a substantial stake in Grail, said it has “received indications of interest” from investors who want to bankroll Grail’s development of a blood test capable of detecting fragments of cancer DNA shed by tumors.